The North America monoclonal antibody therapy market was worth USD 56.42 Billion in 2021 and is estimated to be growing at a CAGR of 15.61%, to reach USD 116.51 Billion by 2026.
Monoclonal antibodies (mAbs), a type of monospecific antibody (protective body inflammatory response), are made up of identical antibody molecules and are produced by a single cell clone or cell line.
One of the primary factors driving the growth of the North America monoclonal antibody therapy market is the increasing prevalence of chronic disorders such as cancer. Chronic diseases are a big burden in the region, leading the government to take measures to reduce the costs associated with their spread. According to the Centers for Disease Control and Prevention, six out of every ten persons in the United States have a chronic disease, resulting in a $ 3.5 trillion yearly healthcare cost.
In addition, unmet patient demands and improved health reimbursement policies for therapeutic monoclonal antibodies utilized as a treatment option for chronic diseases are expected to drive the North America monoclonal antibody therapy market forward.
The large-scale manufacture of mAbs stimulates pharmaceutical companies to develop their own product lines for personalized medicinal products is expected to expand the market growth.
The homogeneity of mAbs also makes them appropriate for experimental methods, as it makes producing similar antibodies easier. As a result, their demand in the healthcare sector is growing.
On the other hand, the increased patient and clinician knowledge of mAb therapy, the introduction of superior products, rising antibody adoption in sensitive markets, and speedy regulatory approval for new monoclonal antibodies therapy are all aspects that are positively impacting the market.
The market for cost-effective biosimilar monoclonal antibody therapy in North America has risen significantly as a result of the increased availability of cost-effective biosimilar monoclonal antibody therapy.
Despite the positive results of monoclonal antibodies in the treatment of numerous diseases, the lengthy and stringent approval and launch procedures will be a big impediment to monoclonal antibody therapy income. In addition, many clinical studies are halted due to a failure to meet the regulatory bodies demanding standards and end findings. Other issues limiting the monoclonal antibody therapy market growth include the drug's potential negative effects.
This research report on the North America monoclonal antibody therapy market has been segmented and sub-segmented into the following categories:
By Distribution Channel:
North America dominated the monoclonal antibody therapy market. The regional market growth is attributed to the availability of well-established healthcare infrastructure, the government emphasis on infection control and management, and a higher frequency of lifestyle-related disorders. The countries such as The United States and Canada are expanding the North America monoclonal antibody therapy market.
The United States is likely to dominate the market in North America. Market growth is being driven by the rapidly increasing number of cancers, increased government investment for cancer research, and technological development. For example, the United States National Institute of Standards and Technology bio-fabrication initiative provides scientifically sound regulatory guidance to ensure the efficient and safe manufacture of protein therapies and assist biopharmaceutical manufacturers in delivering high-quality protein drugs at low costs around the world. According to the American Cancer Society forecasts for the year 2020 in the United States, there would be around 1,855,950 new cancer cases and 606,550 cancer deaths, fuel market demand.
The monoclonal antibody therapy market in Canada is expected to contribute to regional market growth in North America.
KEY MARKET PLAYERS:
Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., CASI Pharmaceuticals, Eli Lilly and Co., Merck & Co., Inc., Changchun Zhongyingfeng Science And Technology Co., Ltd, Hangzhou Immuno Biotech Co. Ltd, Nantong Egens Biotechnology Co. Ltd are some of the dominating companies in the North America monoclonal antibody therapy market.
1.1 Market Definition
1.2 Scope of the report
1.3 Study Assumptions
1.4 Base Currency, Base Year and Forecast Periods
2. Research Methodology
2.1 Analysis Design
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Data Modelling
2.2.4 Expert Validation
2.3 Study Timeline
3. Report Overview
3.1 Executive Summary
3.2 Key Inferences
4. Market Dynamics
4.1 Impact Analysis
4.2 Regulatory Environment
4.3 Technology Timeline & Recent Trends
5. Competitor Benchmarking Analysis
5.1 Key Player Benchmarking
5.1.1 Market share analysis
5.1.3 Regional Presence
5.2 Mergers & Acquistion Landscape
5.3 Joint Ventures & Collaborations
6. Market Segmentation
6.1 North America Monoclonal Antibody Therapy Market - By Type:
6.1.1 Human mAb
6.1.2 Humanized mAb
6.1.3 Chimeric mAb
6.1.4 Murine mAb
6.1.5 Market Size Estimations & Forecasts (2021-2026)
6.1.6 Y-o-Y Growth Rate Analysis
6.1.7 Market Attractiveness Index
6.2 North America Monoclonal Antibody Therapy Market -By Application:
6.2.2 Autoimmune Diseases
6.2.3 Market Size Estimations & Forecasts (2021-2026)
6.2.4 Y-o-Y Growth Rate Analysis
6.2.5 Market Attractiveness Index
6.3 North America Monoclonal Antibody Therapy Market -By Distribution Channel:
6.3.1 Hospital Pharmacy Retail Pharmacy
6.3.2 Online Pharmacy
6.3.3 Market Size Estimations & Forecasts (2021-2026)
6.3.4 Y-o-Y Growth Rate Analysis
6.3.5 Market Attractiveness Index
7. Geographical Landscape
7.1 North America - Market Analysis (2021 - 2026)
7.1.1 By Country
7.1.2 By Type
7.1.3 By Application
7.1.4 By Distribution Channel:
8. Key Player Analysis
8.1 Pfizer Inc.
8.1.1 Business Description
8.1.4 SWOT Analysis
8.1.5 Recent Developments
8.1.6 Analyst Overview
8.2 Novartis AG
8.3 Bayer AG
8.4 Sanofi S.A.
8.5 CASI Pharmaceuticals
8.6 Eli Lilly and Co.
8.7 Merck & Co., Inc.
8.8 Changchun Zhongyingfeng Science And Technology Co., Ltd
8.9 Hangzhou Immuno Biotech Co. Ltd
8.10 Nantong Egens Biotechnology Co. Ltd
9. Market Outlook & Investment Opportunities
List of Tables
List of Figures
Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identify the areas that are still untapped.
The segment-level analysis in terms of type, application, distribution channel, and region along with market size forecasts and estimations to detect key areas of industry growth in detail.
Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.
Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.
Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development.
A comprehensive list of key market players along with their product portfolio, current strategic interests, essential financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment.
Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies
An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.
Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations with a strong financial foothold in the market.
North America Monoclonal Antibody Therapy Market By Type, From 2021 to 2026 ( USD Billion )
North America Human mAb Market By Region, From 2021 to 2026 ( USD Billion )
North America Humanized mAb Market By Region, From 2021 to 2026 ( USD Billion )
North America Chimeric mAb Market By Region, From 2021 to 2026 ( USD Billion )
North America Murine mAb Market By Region, From 2021 to 2026 ( USD Billion )
North America Monoclonal Antibody Therapy Market By Application, From 2021 to 2026 ( USD Billion )
North America Cancer Market By Region, From 2021 to 2026 ( USD Billion )
North America Autoimmune Diseases Market By Region, From 2021 to 2026 ( USD Billion )
North America Monoclonal Antibody Therapy Market By Distribution Channel, From 2021 to 2026 ( USD Billion )
North America Hospital Pharmacy Retail Pharmacy Market By Region, From 2021 to 2026 ( USD Billion )
North America Online Pharmacy Market By Region, From 2021 to 2026 ( USD Billion )
United States Monoclonal Antibody Therapy Market By Type, From 2021 to 2026 ( USD Billion )
United States Monoclonal Antibody Therapy Market By Application, From 2021 to 2026 ( USD Billion )
United States Monoclonal Antibody Therapy Market By Distribution Channel, From 2021 to 2026 ( USD Billion )
Canada Monoclonal Antibody Therapy Market By Type, From 2021 to 2026 ( USD Billion )
Canada Monoclonal Antibody Therapy Market By Application, From 2021 to 2026 ( USD Billion )
Canada Monoclonal Antibody Therapy Market By Distribution Channel, From 2021 to 2026 ( USD Billion )